9 results
The goal of this study is to evaluate the effect of Gladskin on usage of topical corticosteroids in patients with atopic dermatitis. Secondary goals are to retrieve information about the effect of Gladskin on clinical symptoms, quality of life,…
The primary objective is to investigate the rate of pathological responses following different neoadjuvant immunotherapy combinations in high-risk non-metastatic clear cell RCC in an adaptive trial design. And to study the safety and feasibility of…
The aim of this study is to evaluate the effect of Gladskin treatment on the occurrence of skin symptoms in patients with NS. Secondary we want to retrieve information about the effect of Gladskin on quality of life, safety, the load of S. aureus…
Primary Objective: - To evaluate the efficacy of PF-06651600 and PF-06700841 at Week 8 in subjects with moderate to severe UC. Secondary Objective(s): - To evaluate the safety and tolerability of PF-06651600 and PF-06700841 in subjects with moderate…
Part A: To characterize the safety, tolerability, and define the MTD or RP2D for the combination of relatlimab + nivolumab in pediatric participants less than 18 years of age with R/R cHL and NHL.Part A: To characterize the PK of relatlimab for the…
Primary Objective:The primary objective of this study is to determine the feasibility of four weeks of preoperative immunotherapy with Arm A nivolumab (240 mg q2w), Arm B nivolumab (240 mg q2w) plus relatlimab (80 mg q2w), and arm C nivolumab (240…
Primary Objective: To determine the safety and feasibility of pre-operative immunotherapy in CRC. Additional Primary Objective for the expanded the MSI cohort: To assess efficacy of neoadjuvant ipilimumab plus nivolumab in terms of disease-free…
Primary objectiveTo determine the pathological complete response rate per cohort
Part 1: dose safety confirmationPrimary: To evaluate the proportion of participants with TRAEs leading to discontinuation within 12 weeks after the first dose of nivolumab plus2 different dose levels of relatlimab (360 mg and 720 mg) in combination…